Table 1.

Associations between 14 SNPs and lung cancer risk with P < 0.05 after FDR-correction

SNP	Chr	Positiona	Gene	Alleleb	EAFc	OR (95% CI)d	P d	P FDR e	Effectsf	P hete g	I 2
rs3115672	6	31727897	MSH5	C/T	0.106	1.20 (1.14–1.27)	3.99E-11	3.30E-08	+ + + + + +	0.266	22.30
rs114596632	6	30879987	GTF2H4	C/T	0.114	1.19 (1.12–1.25)	5.40E-10	2.23E-07	+ + + + + +	0.462	0.00
rs3748522	12	1058688	RAD52	C/A	0.481	0.92 (0.89–0.95)	2.11E-06	5.81E-04	− − − − + +	0.108	44.61
rs11571475	12	1022352	RAD52	A/G	0.134	0.90 (0.85–0.95)	3.32E-05	6.86E-03	− − − − + −	0.641	0.00
rs1056503	5	82648977	XRCC4	T/G	0.120	1.11 (1.06–1.18)	6.23E-05	8.02E-03	+ + + + + +	0.515	0.00
rs506120	15	43802024	TP53BP1	C/T	0.279	0.92 (0.89–0.96)	6.53E-05	8.02E-03	− − − − + −	0.420	0.00
rs11571376	12	1059556	RAD52	C/G	0.290	0.92 (0.89–0.96)	6.96E-05	8.02E-03	− + − − − −	0.113	43.82
rs12563994	1	155244092	CLK2	C/T	0.243	1.09 (1.04–1.13)	7.77E-05	8.02E-03	+ − + + − +	0.200	31.39
rs7334543	13	32973276	BRCA2	A/G	0.256	0.93 (0.89–0.96)	1.49E-04	1.37E-02	− − − − + −	0.208	30.32
rs707937	6	31731014	MSH5	C/G	0.180	0.91 (0.87–0.96)	2.30E-04	1.90E-02	− − + − − −	0.234	26.79
rs2035990	5	82649467	XRCC4	T/C	0.069	1.13 (1.06–1.21)	3.63E-04	2.73E-02	+ + + + + +	0.106	44.97
rs28628574	15	43802038	TP53BP1	A/C	0.103	0.90 (0.85–0.95)	4.05E-04	2.79E-02	− − + − − −	0.960	0.00
rs9534160	13	32888021	BRCA2	G/A	0.049	1.15 (1.06–1.25)	7.65E-04	4.56E-02	+ + + + + −	0.433	0.00
rs4246215	11	61564299	FEN1	G/T	0.358	0.94 (0.91–0.97)	7.73E-04	4.56E-02	− − − − − +	0.120	42.76

SNP, single nucleotide polymorphisms; FDR, false discovery rate; Chr, chromosome.

^aBased on NCBI build 37 of the human genome.

^bReference allele/effect allele.

^cEffect allele frequency.

^dMeta-analysis additive model P-value based on six lung cancer GWASs.

^eFalse discovery rate (FDR) correction.

^fEffects by study: ICR, MDACC, IARC, NCI, SLRI and GLC, respectively. + represents OR > 1.00, and − represents OR < 1.00.

^g P value for heterogeneity.